Melanoma-associated antigen peptide-HLA class I complex (MAP-HLA-I)

Melanoma-associated antigenic peptides presented by HLA class I molecules are specific molecular complexes displayed on the surface of melanoma cells that serve as primary targets for cellular immunotherapy [PubMed: 22101456]. These complexes consist of short peptide fragments derived from intracellular proteins—such as gp100, MART-1, or MAGE family proteins—bound within the groove of Human Leukocyte Antigen (HLA) class I molecules [UniProt: P43355, P40967]. This presentation is essential for the recognition of malignant cells by the adaptive immune system, specifically by CD8+ cytotoxic T lymphocytes [Janeway's Immunobiology]. Therapeutic strategies targeting these complexes include T-cell receptor (TCR) engineered T-cells and bispecific T-cell engagers, which bypass traditional immune checkpoints to directly induce tumor lysis [PubMed: 35045221]. A clinically validated example is tebentafusp, which targets a gp100 peptide presented by HLA-A*02:01 to treat uveal melanoma [FDA, 2022]. While highly specific, the efficacy of these therapies is often limited by the requirement for specific HLA genotypes in patients and the potential for 'on-target, off-tumor' effects against healthy melanocytes in the skin and eyes [Nature Medicine, 2024]. Furthermore, tumors may develop resistance through the downregulation of HLA molecules or defects in the antigen processing machinery [PubMed: 28945246]. Despite these challenges, the development of TCR-based therapies continues to expand the landscape of targetable intracellular antigens in melanoma.

Other names

Melanoma-associated antigen (MAA)Tumor-associated antigen (TAA) peptide-MHC complexHLA-restricted melanoma antigenMelanoma-specific peptide-HLA complexpMHC complex

Drugs targeting these complexes typically utilize engineered T-cell receptors (TCRs) or bispecific molecules to recognize the specific peptide-HLA assembly, triggering T-cell mediated cytotoxicity against the melanoma cell [PubMed: 35045221].